WO2004047719A2 - Utilisation de derives d'iminosucre pour inhiber l'activite du canal ionique - Google Patents

Utilisation de derives d'iminosucre pour inhiber l'activite du canal ionique Download PDF

Info

Publication number
WO2004047719A2
WO2004047719A2 PCT/IB2003/006471 IB0306471W WO2004047719A2 WO 2004047719 A2 WO2004047719 A2 WO 2004047719A2 IB 0306471 W IB0306471 W IB 0306471W WO 2004047719 A2 WO2004047719 A2 WO 2004047719A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
linear
branched
aryl
group
Prior art date
Application number
PCT/IB2003/006471
Other languages
English (en)
Other versions
WO2004047719A3 (fr
Inventor
Nicole Zitzmann
Raymond Dwek
Original Assignee
The Chancellor, Masters And Scholars Of The University Of Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Chancellor, Masters And Scholars Of The University Of Oxford filed Critical The Chancellor, Masters And Scholars Of The University Of Oxford
Priority to CA002500940A priority Critical patent/CA2500940A1/fr
Priority to EP03811849A priority patent/EP1556036A2/fr
Priority to AU2003302370A priority patent/AU2003302370A1/en
Priority to JP2004554867A priority patent/JP2006515577A/ja
Publication of WO2004047719A2 publication Critical patent/WO2004047719A2/fr
Publication of WO2004047719A3 publication Critical patent/WO2004047719A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • HCV Hepatitis C virus
  • HCV Di Bisceglie, A.M., ( 1 997) Hepatology 26(3 Suppl. 1 ) : 345-385). HCV belongs
  • Flaviviridae which consists of three genera: flaviviruses,
  • BVDV bovine viral diarrhea virus
  • analogue 1 ,5-Dideoxy-1 ,5-imino-D-galactitol also called
  • DGJ deoxygalactonojirimycin
  • DNJ derivatives are antiviral inhibitors at least partially because they
  • Calnexin interaction is crucial for the proper folding of many host and
  • virus encoded glycoproteins including the envelope glycoproteins of BVDV and
  • envelope glycoproteins may lead to an impaired secretion of virions from
  • N-DNJ alkylchain derivative N-nonyl-DNJ
  • N-butyl-DNJ N-butyl-DNJ
  • amphiphilic, alkylated iminosugar derivatives as the structurally similar
  • n-octyl glucoside n-OG
  • n-nonyl glucoside n-nonyl glucoside
  • glycoproteins and alters the membrane glycoprotein composition of secreted
  • BVDV virions but does not influence either viral RNA replication or protein
  • DEV DENV
  • JEV Japanese Encephalitis virus
  • pestiviruses Unlike the closer related pesti- and hepaciviruses, flaviviruses do
  • DNJ- and DGJ- derivatives may inhibit viral replication by inhibiting p7 or
  • the HCV positive stranded RNA genome encodes a single polyprotein
  • the polyprotein is co-reacted
  • HCV replication information about HCV replication is derived by using a BVDV cell culture
  • infectious viral particles can be generated by complementing
  • the HCV p7 protein is a 63 amino acid peptide which has been
  • the p7 protein has been shown to include two transmembrane domains.
  • the N- terminal transmembrane domain includes amino acids from about position 1 0
  • transmembrane domains (typically greater than about 70%), are members of a
  • hydrophobic group characterized as F, I, W, Y, L, V, M, P, C, and A.
  • LPQRAYA (SEQ ID NO. : 1 ) .
  • HCV p7 has been
  • viroporins which mediate cation permeability across membranes and are
  • transmembrane domain has been shown to be sufficient to form membrane
  • One embodiment relates to a method of treating HCV infection by
  • HCV p7 protein in a subject in need thereof, particular a human.
  • the compounds are represented by the following Formula I or II :
  • R 31 ' , R 32 , R 32' , R 33 , R 33' , R 34 , and R 34' is selected, independently from each other,
  • dialkylamino linear or branched Ci 6 alkyl, C 2 -6 alkenyl and alkynyl; aralkyl;
  • alkyDthio (Ci e alkyl)sulfonamide; arylsulfonamide; -NHNH 2 ; -NHOH; aryl; and
  • heteroaryl wherein each of the substituents may be the same or different.
  • R 2 and R 4 are substituents selected independently of each other from
  • alkyl C 2 - ⁇ s alkenyl and alkynyl, and aralkyl.
  • Each linear C7-18 alkyl, branched C3- is alkyl, C 2 - ⁇ s alkenyl and alkynyl, and aralkyl optionally may be substituted, and
  • substituted C1-18 alkyl is substituted with one or more substituents
  • alkyl- and dialkylamino linear or branched C1-6 alkyl, C 2 -e alkenyl and alkynyl;
  • aralkyl linear or branched Ci e alkoxy, aryloxy; aralkoxy; -CN; -NO 2 ; -COOH; -
  • alkyDsulfonyl arylsulfonyl; sulfamoyl, (C1-6 alkyDsulfamoyl; (C1-6 alkyDthio; (C1-6
  • alkyDsulfonamide arylsulfonamide; -NHNH 2 ; and -NHOH, wherein selected
  • N-DNJ N-nonyldeoxynojirimycin
  • oxaundecyl-1 ,6-dideoxygalactonojirimycin i.e. , N-1 0-oxaundecyl-6-
  • One or more of the compounds may be packaged as a kit for treating
  • the kit may include instructions for treating HCV infection as
  • Another embodiment relates to a method of screening compounds for
  • FIGURE 1 A shows the growth curves of E. co/i Rosetta gami(DE3)pLacl
  • FIGURE 1 B shows the release of [ 3 H]-uridine by non-transformed E. co/i Rosetta
  • FIGURE 2 shows a Tris-tricine gel electrophoresis analysis of synthetic
  • the gel was silver-stained (left panel) or transferred to a membrane
  • FIGURE 3A shows channel recordings of synthetic HCV p7
  • FIGURE 3B is reconstituted into a BLM. Straight lines denote the closed state.
  • FIGURE 3B is reconstituted into a BLM. Straight lines denote the closed state.
  • FIGURE 3C shows a current histogram of the trace recorded at
  • FIGURE 4 shows the effect of the short ( ⁇ B-DNJ, NB-DGJ) and long
  • iminosugar derivatives were added to a final concentration as indicated.
  • FIGURE 5 shows the effect of N7-oxanonyl-6-deoxy-DGJ (alternatively
  • N7-oxanonyl-methyl-DGJ N7-oxanonyl-methyl-DGJ
  • FIGURE 6 shows a graphical representation of the normalized
  • the data represent the average of three representative trace slices of 4
  • Ka PP 1 1 0.4 ( ⁇ 1 9.9) ⁇ M; and for N7-oxanonyl-6-deoxy-DGJ, Ka PP
  • FIGURE 7 shows the effect of SP240 (i.e. , N-1 0-oxaundecyl-1 ,6-
  • atoms and includes, for example, methyl, ethyl, butyl, and nonyl.
  • aryl refers to a monocyclic aromatic group
  • phenyl such as phenyl or a benzo-fused aromatic group such as indanyl, naphthyl, or
  • heteroaryl refers to aromatic compounds containing one
  • hetero atoms examples include pyridyl, furyl, and thienyl or a
  • benzofused aromatic containing one or more heteroatoms such as indolyl or
  • heteroatom refers to non-carbon atoms
  • cycloalkyl refers to a carbocyclic ring
  • alkenyl refers to a straight or branched-
  • chain alkyl containing one or more double bonds such as ethenyl and propenyl.
  • aralkyl refers to an alkyl substituted with
  • an aryl such as benzyl and phenethyl.
  • alkynyl refers to a straight or branched-
  • aryloxy refers to a substituent created by
  • replacing the hydrogen atom in an -OH group with an aryl group includes,
  • alkoxy refers to an alkoxy group
  • alkylamino refers to an amino group
  • alkyl group such as methylamino (-NHCH3) and
  • dialkylamino refers to an amino group
  • DNG means 1 ,5-Dideoxy-1 ,5-imino-D-
  • DGJ means 1 ,5-Dideoxy-1 ,5-imino-D-
  • BLM black lipid membranes
  • the method contemplates administering compounds of
  • R 1 1 , R 1 1 ' , R 12 , R 12' , R 13 , R 13' , R 14 , R 14' , R 15 , and R 15' is
  • alkenyl and alkynyl aralkyl; linear or branched Ci e alkoxy; aryloxy; aralkoxy; -
  • alkyl -C(O)NH(aryl); sulfonyl; (C1-6 alkyDsulfonyl; arylsulfonyl; sulfamoyl, (C1-6
  • alkyDsulfamoyl (Ci-e alkyDthio; (C1-6 alkyDsulfonamide; arylsulfonamide; -
  • R 14 , R 14' , R 15 , and R 15' is a hydroxymethyl group (-CH 2 OH).
  • R 1 1 , R 1 V , R 12 , R 12' , R 13 , R 13' , R 14 , R 14' , R 15 , and R 15' is a hydroxy
  • R 1 1 , R 1 1 ' , R 12 , R 12' , R 13 , R 13' , R 14 , R 14' , R 15 , and R 15' being selected from -CHs, -
  • R 2 is a substituent selected from linear C7- ⁇ s alkyl, substituted CM S
  • alkyl is alkyl, branched C 3 - ⁇ s alkyl, C 2 - ⁇ alkenyl and alkynyl, and aralkyl optionally
  • dialkylamino linear or branched C1-6 alkyl, C 2 -6 alkenyl and alkynyl; aralkyl;
  • alkyDsulfonyl arylsulfonyl; sulfamoyl, (C1-6 alkyDsulfamoyl; (C1-6 alkyDthio; (C1-6
  • alkyDsulfonamide arylsulfonamide; -NHNH 2 ; and -NHOH.
  • R 2 is a linear C7-18 alkyl, branched C3-18 alkyl, or
  • R 2 is a linear C7-11 alkyl
  • R 2 that are linear C7-11 alkyl
  • substituents include heptyl, octyl, and nonyl.
  • R 2 being a
  • substituted alkyl group is 7-oxanonyl (-CH 2 (CH 2 )5-O-CH 2 CH 3 ).
  • -CH 2 (CH 2 )5-O-CH 2 CH 3 7-oxanonyl
  • R 2 is n-nonyl, 7-oxanonyl, or 1 0-oxaundecyl.
  • the compound may be represented as one of the following formulas:
  • the compound has one of the formulas as set forth in Table I:
  • the compound has one of the formulas:
  • R 2 is nonyl, 7-oxanonyl, or 10-oxaundecyl
  • N-DNJ N-nonyldeoxynojirimycin
  • oxaundecyl-1 ,6-dideoxygalactonojirimycin i.e. , N-10-oxaundecyl-6-
  • Another aspect of the disclosed method contemplates administering
  • R 31 , R 31 ' , R 32 , R 32' , R 33 , R 33' , R 34 , and R 34' is
  • alkenyl and alkynyl aralkyl; linear or branched C1-6 alkoxy; aryloxy; aralkoxy; -
  • alkyl -C(0)NH(aryl); sulfonyl; (Ci-e alkyDsulfonyl; arylsulfonyl; sulfamoyl, (Ci-e
  • alkyDsulfamoyl (Ci - ⁇ alkyDthio; (C1-6 alkyDsulfonamide; arylsulfonamide; -
  • R 34 , and R 34" is a hydroxymethyl group (-CH 2 OH).
  • R 1 1 , R 1 1 ' , R 12 , R 12' , R 13 , R 13' , R 14 , R 14' , R 15 , and R 15' is a hydroxy group (-OH) .
  • the most preferred embodiment contemplates at least two of R 11 , R 1 1 , R 12 ,
  • R 12' , R 13 , R 13' , R 14 , R 14' , R 15 , and R 15' being selected from -CH 3 , -CH 2 OH, and -
  • R 4 is a substituent selected from linear C7- ⁇ alkyl
  • aralkyl Each linear C7- ⁇ s alkyl, branched C3-18 alkyl, C 2 - ⁇ 8 alkenyl and alkynyl,
  • aralkyl linear or branched C1-6 alkoxy, aryloxy; aralkoxy; -CN; - NO 2 ; -COOH; -COO(alkyl); -COO(aryl); -C(O)NH(C ⁇ -e alkyl); -C(O)NH(aryl);
  • alkyDthio (Ci-e alkyDsulfonamide; arylsulfonamide; -NHNH 2 ; and -NHOH.
  • R 4 is a linear C7-18 alkyl, branched C3-18 alkyl, or
  • R 4 is a linear C7-11 alkyl
  • R 4 that are linear C7-11 alkyl
  • substituents include heptyl, octyl, and nonyl.
  • R 4 being a
  • substituted alkyl group is 7-oxanonyl (-CH 2 (CH 2 )5-O-CH 2 CH 3 ).
  • -CH 2 (CH 2 )5-O-CH 2 CH 3 7-oxanonyl
  • R 4 is A?-nonyl, 7-oxanonyl, or 1 0-undecyl.
  • a membrane that includes the p7 protein with one or more compounds that
  • particular compounds can inhibit the ability of p7 to permeabilize membranes.
  • the selected compound may inhibit one or more activities of the p7
  • the compound may prevent p7 from forming
  • channels, or the compound may block the channel after it has formed, (i.e. , as
  • the compound may inhibit the p7 protein by
  • the compound may inhibit the capability of p7 to
  • method comprises incorporating p7 or a variant of p7 into a membrane system
  • Black lipid membranes may be used in the method, but other organic solvents (e.g., but other organic solvents (e.g., organic solvents (OLED), organic solvents (OLED), organic solvents (OLED), organic solvents (OLED), organic solvents (OLED), organic solvents (OLED), organic solvents (OLED), organic solvents (OLED), organic solvents (OLED), organic solvents (OLED), organic solvents (OLED), organic solvent, but other organic solvent, but other organic solvent, but other organic solvent, but other organic solvents (OLED).
  • BLM are commonly used to study membrane permeability, e.g. , as mediated by channel-forming proteins.
  • p7 may be incorporated into the membranes to form p7-containing
  • the p7 protein may be selected from any HCV strain where the
  • p7 protein can be shown to increase the permeability of a selected membrane.
  • the p7 protein from the HCV-H strain may be selected (i.e. ,
  • LPQRAYA SEQ ID NO.: 1
  • p7 protein from another strain may be any suitable p7 protein from another strain.
  • a p7 protein from a particular HCV clade, (e.g. , clade 1 ).
  • the variant may be shown to permeabilize a chosen membrane
  • Possible variants include fusions,
  • deletions, and/or mutations or substitutions may be desirable.
  • p7 that can be shown to permeabilize a chosen membrane (e.g. , a selected
  • p7 protein or variant may demonstrate a conductance level in a BLM of no less
  • a "hydrophobic amino acid” may be
  • the chosen p7 protein or variant may be synthesized artificially or
  • a suitable biological system such as bacterial or eukaryotic cells.
  • the permeability of the membranes may be measured to determine whether the
  • protein demonstrates activity (e.g. , causing an increase in permeability or a
  • Test compounds may be contacted with the protein
  • test compounds may be contacted with p7 and/or the components of the p7-
  • test compounds in the screening method.
  • N-1 0- oxaundecyl-1 ,6-dideoxygalactonojirimycin i.e. , N-1 0-oxaundecyl-6-
  • membrane components as test compounds in the method e.g. , compounds
  • amantadine is a known channel blocker of influenza A virus M2 channels. (See
  • an inducible bacterial system may be utilized to generate a plurality of cells.
  • membranes may lead to an arrest in cell growth.
  • p7 or a variant thereof may be expressed from an inducible promoter in a suitable bacteria
  • radioactive molecule such as [ 3 H]-uridine prior to induction of p7 expression.
  • Test compounds may be any organic compound having the release of [ 3 H]-uridine into the media.
  • Test compounds may be any organic compound having the release of [ 3 H]-uridine into the media.
  • the present compounds can be prepared by synthetic
  • the medicaments may be adapted for administration by any means.
  • Such a composition may be prepared
  • bitartrate bromide, calcium edetate, camsylate, carbonate, citrate, edetate,
  • estolate estolate
  • esylate fumarate
  • gluceptate gluconate
  • glutamate glutamate
  • glycollylarsanilate hexylresorcinate, hydrabamine, hydrobromide
  • salicylate stearate, subacetate, succinate, sulfate, tannate, tartrate, or
  • Preferred pharmaceutically acceptable salts include, for example,
  • hydrochloride maleate, mesylate, napsylate, pamoate (embonate), phosphate,
  • the compounds and agents may be formulated in
  • aqueous solutions preferably in physiologically compatible buffers such as
  • penetrants are generally known
  • compositions suitable for use in the present methods are provided.
  • compositions wherein the active ingredients are contained in an
  • compositions may contain suitable pharmaceutically acceptable carriers
  • preparations formulated for oral administration may be in the form of tablets,
  • methods provided herein may include one or more of the following: preserving
  • sweeteners colorants, odorants, salts, buffers, coating agents or antioxidants.
  • oral use can be obtained by combining the active compounds with solid
  • Suitable excipients are, in particular, fillers such as sugars,
  • cellulose preparations for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum
  • tragacanth methyl cellulose, hydroxypropylmethyl-cellulose, sodium
  • CMC carboxymethyl-cellulose
  • PVP polyvinylpyrrolidone
  • disintegrating agents may be added, such as the cross-linked
  • polyvinylpyrrolidone agar, or alginic acid or a salt thereof such as sodium
  • compositions which can be used orally include push-fit
  • capsules made of gelatin as well as soft, sealed capsules made of gelatin, and
  • the push-fit capsules can contain the following plasticizer, such as glycerol or sorbitol.
  • a plasticizer such as glycerol or sorbitol.
  • the push-fit capsules can contain the following plasticizer, such as glycerol or sorbitol.
  • starches, and/or lubricants such as talc or magnesium stearate and, optionally,
  • the active compounds may be dissolved or
  • liquids such as fatty oils, liquid paraffin, or liquid
  • PEGs polyethylene glycols
  • stabilizers may be added.
  • Medicaments adapted for oral administration may be provided as
  • capsules or tablets as powders or granules; as solutions, syrups or
  • suspensions in aqueous or non-aqueous liquids); as edible foams or whips; or
  • Tablets or hard gelatin capsules may comprise lactose, maize starch
  • Soft gelatin capsules may comprise vegetable oils, waxes, fats, semi-
  • Solutions and syrups may comprise water, polyols and sugars.
  • suspensions oils e.g. , vegetable oils
  • Medicaments adapted for transdermal administration may be provided
  • ingredient may be delivered from the patch by iontophoresis (Iontophoresis is
  • Medicaments adapted for topical administration may be provided as
  • a topical ointment or cream is preferably used.
  • a topical ointment or cream is preferably used.
  • the active ingredient may be employed with either a paraffinic or
  • the active ingredient may be any suitable ointment base.
  • the active ingredient may be any suitable ointment base.
  • the active ingredient may be any suitable ointment base.
  • the active ingredient may be any suitable ointment base.
  • the active ingredient may be any suitable ointment base.
  • the active ingredient may be any suitable ointment base.
  • Medicaments adapted for topical administration to the eye include
  • the active ingredient can be dissolved or suspended in a
  • Suitable carrier e.g. , in an aqueous solvent.
  • Medicaments adapted for topical administration in the mouth include
  • Medicaments adapted for rectal administration may be provided as
  • carriers include a coarse powder (e.g. , having a particle size in the range of 20
  • compositions adopted for nasal administration which use liquid
  • nasal sprays or nasal drops include nasal sprays or nasal drops. These may comprise aqueous or
  • Medicaments adapted for administration by inhalation include fine particles
  • particle dusts or mists which may be generated by means of various types of
  • apparatus e.g. , pressurized aerosols, nebulizers or insufflators.
  • apparatus can be constructed so as to provide predetermined dosages of the
  • Medicaments adapted for parenteral administration include aqueous
  • compositions substantially isotonic with the blood of an intended recipient.
  • compositions include water,
  • compositions for example, alcohols, polyols, glycerine and vegetable oils, for example.
  • adapted for parenteral administration may be presented in unit-dose or multi-
  • dose containers for example sealed ampoules and vials, and may be stored in
  • liquid carrier e.g. , sterile water for injections, immediately prior to use.
  • active agent 0.1 mg to 5 g of active agent, and may be in the range of from
  • the dosage may be administered in a single
  • EXAMPLE 1 Inducible p7 expression in bacteria.
  • p7 expression effects a release in radioactively labeled uridine.
  • Example 1 .1 Materials and Methods.
  • the coding region of HCV p7 was amplified by polymerase
  • PCR chain reaction
  • HCV 1 a strain cDNA (AF009606), kindly provided by J. Dubuisson. PCR
  • AAGCGCCCATGGCTTTGGAGAACCTCGTAATAC (SEQ ID NO. : 2) and 2,
  • the ligation mixture was used to transform competent E. coli R. garni
  • plasmid was amplified in 50 ⁇ g/ml carbenicillin (Sigma) containing medium.
  • pTriEx1 .1 p7 isolated p7-containing plasmid was designated pTriEx1 .1 p7.
  • IPTG isopropylthiogalactopyranoside
  • Rosetta garni (DE3)pLacl cells carry a
  • Example 2.1 Materials and Methods.
  • LPQRAYA (SEQ ID NO.: 4)
  • MALDI-MS spectrometry
  • the source, extraction, and focusing voltages were 20000,
  • Tricine sample buffer was applied in Tricine sample buffer to a gel (8 x 1 0 cm 2 ) consisting of
  • the gel was washed for 1 0 min in 50% methanol and for 10
  • portion of the loaded protein contained the full-length, biotinylated p7 protein.
  • This broad band may
  • POPC oleoyl-srj-glycero-3-phosphocholine
  • the BLM was formed by raising the
  • NB-DNJ (Sigma) and NB-DGJ were added on either the cis or trans side.
  • the channels had a conductance level of up to 2 nS at - 1 00 mV ( Figure 3A). The smallest mean conductance level detected was around
  • Table 1 Conductance levels of p7. Data are derived from the recordings in
  • Fig. 3A and presented as the mean value ⁇ the standard error of the mean, as shown in brackets.
  • the mean was calculated from 1 second slices of the recordings.
  • recording may indicate the presence of sub-conductance states.
  • TMD I transmembrane domain I
  • TMD II transmembrane domain II
  • N-octylglucoside up to 3.0 mM, had no effect on channel activity.
  • alkylchain derivatives NN-DGJ, NN-DNJ and N7-oxanonyl-6-deoxy-DGJ led to a
  • Ka PP 1 1 0.4 ( ⁇ 1 9.9) ⁇ M for NN-DGJ, Ka PP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Méthodes et kits permettant de traiter l'infection due au virus de l'hépatite C (VHC) par administration d'un composé dérivé d'iminosucre capable d'inhiber l'activité de la protéine p7 de VHC, et méthodes permettant de cribler des composés qui inhibent l'activité de la protéine p7 ou des variantes de ladite protéine. Les composés imino à substitution N selon la présente invention et les compositions pharmaceutiques les contenant inhibent la capacité de p7 de VHC de perméabiliser les membranes. Les iminosucres dérivés de pipéridines N-alkylées sont des composés particulièrement efficaces. La présente invention concerne également des méthodes de criblage d'agents antiviraux potentiels contre le VHC.
PCT/IB2003/006471 2002-09-23 2003-09-23 Utilisation de derives d'iminosucre pour inhiber l'activite du canal ionique WO2004047719A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002500940A CA2500940A1 (fr) 2002-09-23 2003-09-23 Utilisation de derives d'iminosucre pour inhiber l'activite du canal ionique
EP03811849A EP1556036A2 (fr) 2002-09-23 2003-09-23 Utilisation de derives d'iminosucre pour inhiber l'activite du canal ionique
AU2003302370A AU2003302370A1 (en) 2002-09-23 2003-09-23 Use of iminosugar derivatives to inhibit ion channel activity
JP2004554867A JP2006515577A (ja) 2002-09-23 2003-09-23 イオンチャネル活性を阻害するためのイミノ糖誘導体の使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41256002P 2002-09-23 2002-09-23
US60/412,560 2002-09-23

Publications (2)

Publication Number Publication Date
WO2004047719A2 true WO2004047719A2 (fr) 2004-06-10
WO2004047719A3 WO2004047719A3 (fr) 2005-05-26

Family

ID=32393265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/006471 WO2004047719A2 (fr) 2002-09-23 2003-09-23 Utilisation de derives d'iminosucre pour inhiber l'activite du canal ionique

Country Status (7)

Country Link
EP (1) EP1556036A2 (fr)
JP (1) JP2006515577A (fr)
KR (1) KR20050092103A (fr)
CN (1) CN1694696A (fr)
AU (1) AU2003302370A1 (fr)
CA (1) CA2500940A1 (fr)
WO (1) WO2004047719A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
US8557764B2 (en) 2007-01-26 2013-10-15 The Regents Of The University Of Colorado, A Body Corporate Methods of modulating immune function
US8921568B2 (en) 2012-06-06 2014-12-30 Unither Virology, Llc Iminosugars and their applications
US8957031B2 (en) 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120042716A (ko) * 2009-02-23 2012-05-03 유나이티드 세러퓨틱스 코오포레이션 이미노슈가 및 바이러스성 질환을 치료하는 방법
CN113150076B (zh) * 2021-03-03 2022-05-31 天津医科大学 环五肽的合成方法及其在抗丙肝药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0445098A2 (fr) * 1990-02-26 1991-09-04 G.D. SEARLE & COMPANY Dérivés du déoxynojirimycine comme agents antiviraux
US5310745A (en) * 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
WO1998035685A1 (fr) * 1997-02-14 1998-08-20 G.D. Searle And Co. Utilisation de composes de n-substitue-1,5-didesoxy-1,5-imino-d-glucitol dans des traitements associes contre des infections provoquees par des virus de l'hepatite
WO2000047198A2 (fr) * 1999-02-12 2000-08-17 G.D. Searle & Co. Utilisation de composes substitues 1,5-dideoxy-1,5-imino-d-glucitol pour traiter les infections par le virus de l'hepatite
WO2001010429A2 (fr) * 1999-08-10 2001-02-15 The Chancellor, Masters, And Scholars Of The University Of Oxford Composes n-alkyle a longue chaine et leurs derives oxa
WO2001060366A1 (fr) * 2000-02-14 2001-08-23 Pharmacia Corporation Utilisation de composes 1,5-didesoxy-1,5-imino-d-glucitol n-substitues pour le traitement des infections par un virus d'hepatite

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310745A (en) * 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
EP0445098A2 (fr) * 1990-02-26 1991-09-04 G.D. SEARLE & COMPANY Dérivés du déoxynojirimycine comme agents antiviraux
WO1998035685A1 (fr) * 1997-02-14 1998-08-20 G.D. Searle And Co. Utilisation de composes de n-substitue-1,5-didesoxy-1,5-imino-d-glucitol dans des traitements associes contre des infections provoquees par des virus de l'hepatite
WO2000047198A2 (fr) * 1999-02-12 2000-08-17 G.D. Searle & Co. Utilisation de composes substitues 1,5-dideoxy-1,5-imino-d-glucitol pour traiter les infections par le virus de l'hepatite
WO2001010429A2 (fr) * 1999-08-10 2001-02-15 The Chancellor, Masters, And Scholars Of The University Of Oxford Composes n-alkyle a longue chaine et leurs derives oxa
WO2001060366A1 (fr) * 2000-02-14 2001-08-23 Pharmacia Corporation Utilisation de composes 1,5-didesoxy-1,5-imino-d-glucitol n-substitues pour le traitement des infections par un virus d'hepatite

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EGGER D ET AL: "Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 76, no. 12, June 2002 (2002-06), pages 5974-5984, XP002973294 ISSN: 0022-538X *
N ZITZMANN AND ALL.: "Imino sugars inhibit the formation and secretion of bovine viral diarrhea, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum ant-hepatitis virus agents" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 96, no. 21, 12 October 1999 (1999-10-12), pages 11878-11882, XP002293887 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557764B2 (en) 2007-01-26 2013-10-15 The Regents Of The University Of Colorado, A Body Corporate Methods of modulating immune function
US8957031B2 (en) 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
US10420813B2 (en) 2007-10-23 2019-09-24 The Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
US8921568B2 (en) 2012-06-06 2014-12-30 Unither Virology, Llc Iminosugars and their applications

Also Published As

Publication number Publication date
AU2003302370A1 (en) 2004-06-18
WO2004047719A3 (fr) 2005-05-26
AU2003302370A8 (en) 2004-06-18
KR20050092103A (ko) 2005-09-20
CA2500940A1 (fr) 2004-06-10
CN1694696A (zh) 2005-11-09
EP1556036A2 (fr) 2005-07-27
JP2006515577A (ja) 2006-06-01

Similar Documents

Publication Publication Date Title
US7256005B2 (en) Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
ES2347822T3 (es) Inhibidores de replicacion de vhc.
KR101755058B1 (ko) 특정 ｈｃｖ ｎｓ５ａ 억제제 및 ｈｃｖ ｎｓ３ 프로테아제 억제제의 조합물
Steinmann et al. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus
Wu et al. Antiviral effects of an iminosugar derivative on flavivirus infections
JP5030587B2 (ja) 抗ウイルスアシルグアニジン化合物および方法
Botta et al. Drug repurposing approaches to fight Dengue virus infection and related diseases
Griffin et al. Genotype‐dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel
EA012650B1 (ru) ПРИМЕНЕНИЕ [D-MeAla]-[EtVal]-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ [D-MeAla]-[EtVal]-ЦИКЛОСПОРИН
EP2374464A2 (fr) Inhibition de la protéase N3S-NS4A du virus de l'hépatite C
US6689759B1 (en) Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
AU2015334590B2 (en) Therapy for inhibition of single-stranded RNA virus replication
JP2008519066A (ja) ウイルス感染症を処置するためのアンドログラフォライド（ａｎｄｒｏｇｒａｐｈｏｌｉｄｅ）誘導体
JP2009510122A (ja) ウイルスペプチドおよびフラビウイルス科のウイルスに対してウイルス感染を阻害するためのその使用
JP2004504356A (ja) Ｃ型肝炎ウイルスのプロセシングおよび複製の抑制
WO2011063076A1 (fr) Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
EP1007058A1 (fr) UTILISATION DE COMPOSES DE $i(N)-SUBSTITUE-1,5-DIDESOXY-1,5-IMINO-D-GLUCITOL DANS DES TRAITEMENTS ASSOCIES CONTRE DES INFECTIONS PROVOQUEES PAR DES VIRUS DE L'HEPATITE
EP1556036A2 (fr) Utilisation de derives d'iminosucre pour inhiber l'activite du canal ionique
US20110212986A1 (en) Anti-flavivirus therapeutic
Zitzmann et al. Use of iminosugar derivatives to inhibit ion channel activity
Karim et al. Symmetric benzidine derivatives as anti-HCV agents: Insight into the nature, stereochemistry of the capping amino acid and the size of the terminal capping carbamates
WO2022251679A1 (fr) Radicaux nitroxyde destinés à être utilisés comme traitement antiviral contre une infection à coronavirus
KR20210069086A (ko) 병원체 활성 조절을 위한 제제 및 방법
WO2005039503A2 (fr) Inhibiteurs de prenylation reduisant la permissivite de la replication virale dans les cellules hotes
JPWO2007043640A1 (ja) Ｈｃｖ感染症を治療または予防するための薬剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1020057004647

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2500940

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004554867

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003811849

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038252007

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003811849

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057004647

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2003811849

Country of ref document: EP